BBNX on Nasdaq
Beta Bionics, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with NeuroPace Inc, KESTRA MEDICAL TECHNOLOGIES, LTD. or Intersect ENT, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
55.4%Gross margin3
-71.5%Operating margin3
-73.0%Net margin3
53.9%Revenue growth, 20253
-25.5%Return on equity3
-$56.2MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue45¢$44.7M
- Research and development35¢$34.8M
- Other costs21¢$20.7M
Out of $100.3M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net sales | $100.3M | $65.1M |
| Cost of sales | $44.7M | $29.2M |
| Gross profit | $55.5M | $35.9M |
| Research and development | $34.8M | $26.2M |
| Sales and marketing | $61.4M | $37.1M |
| General and administrative | $31.0M | $17.9M |
| Total operating expenses | $127.2M | $81.1M |
| Loss from operations | -$71.7M | -$45.3M |
| Interest income | $10.9M | $3.9M |
| Other expense | -$1.0K | -$2.0K |
| Change in fair value of warrant liabilities | -$12.4M | -$13.4M |
| Total other expense, net | -$1.5M | -$9.5M |
| Net loss | -$73.2M | -$54.8M |
| Unrealized gain (loss) on short-term and long-term investments | $338.0K | -$72.0K |
| Comprehensive loss | -$72.9M | -$54.8M |
| Net loss per share attributable to common stockholders, basic | -$1.81 | -$8.60 |
| Net loss per share attributable to common stockholders, diluted | -$1.81 | -$8.60 |
| Weighted-average common shares outstanding, basic | 40.5M shares | 6.4M shares |
| Weighted-average common shares outstanding, diluted | 40.5M shares | 6.4M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $31.6M | $30.4M | |
| Restricted cash, current | $100.0K | ||
| Short-term investments | $187.5M | $73.1M | |
| Accounts receivable, net | $17.1M | $12.0M | |
| Inventories, net | $21.7M | $13.3M | |
| Prepaid expenses and other current assets | $9.8M | $4.0M | |
| Total current assets | $267.9M | $132.9M | |
| Property and equipment, net | $8.6M | $4.8M | |
| Operating lease right-of-use asset | $6.6M | $6.6M | |
| Restricted cash, noncurrent | $100.0K | ||
| Deferred offering costs | $5.1M | ||
| Long-term investments | $45.4M | ||
| Other long-term assets | $180.0K | $150.0K | |
| Total assets | $328.7M | $149.6M | |
| Accounts payable | $5.0M | $2.9M | |
| Accrued expenses and other current liabilities | $22.4M | $15.8M | |
| Operating lease liabilities | $1.9M | $1.5M | |
| Deferred revenue | $1.6M | $939.0K | |
| Total current liabilities | $30.9M | $21.1M | |
| Operating lease liabilities, net of current portion | $5.4M | $5.7M | |
| Deferred revenue, net of current portion | $3.3M | $1.9M | |
| Warrant liabilities | $44.9M | ||
| Other long-term liabilities | $1.5M | ||
| Total liabilities | $41.1M | $73.6M | |
| Convertible preferred stock (Series A, A-2, B, B-2, C, D and E), par value of $0.0001 per share; no and 34,966,547 shares authorized at December 31, 2025 and December 31,2024, respectively; no and 17,228,954 shares issued and outstanding at December 31, 2025 and December 31,2024, respectively; liquidation preference of no and $355,162 at December 31, 2025 and December 31,2024, respectively | $321.4M | ||
| Common stock | $4.0K | $1.0K | |
| Additional paid-in capital | $657.1M | $51.3M | |
| Accumulated other comprehensive income | $403.0K | $65.0K | |
| Accumulated deficit | -$369.9M | -$296.7M | |
| Total stockholders' equity (deficit) | $287.6M | -$245.4M | -$203.1M |
| Total liabilities, convertible preferred stock and stockholders' equity (deficit) | $328.7M | $149.6M | |
| Convertible preferred stock, par value | $0.00 | $0.00 | |
| Convertible preferred stock, shares authorized | 0 shares | 35.0M shares | |
| Convertible preferred stock, shares issued | 0 shares | 17.2M shares | |
| Convertible preferred stock, shares outstanding | 0 shares | 17.2M shares | |
| Convertible preferred stock, liquidation preference | $0 | $355.2M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred Stock, Shares Issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 700.0M shares | 700.0M shares | |
| Common stock, shares issued | 44.4M shares | 6.7M shares | |
| Common stock, shares outstanding | 44.4M shares | 6.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Income (Loss) | -$73.2M | -$54.8M |
| Depreciation expense | $1.6M | $1.2M |
| Provision for expected credit losses | $40.0K | $70.0K |
| Stock-based compensation expense | $16.4M | $6.4M |
| Net provision for excess and obsolete inventory | $1.5M | -$636.0K |
| Change in fair value of warrant liabilities | $12.4M | $13.4M |
| Accretion of discount on short-term investments | -$2.1M | -$2.9M |
| Amortization of premium on long-term investments | $63.0K | |
| Amortization of operating lease right-of-use asset | $1.3M | $1.1M |
| Loss on disposal of property and equipment | $31.0K | $23.0K |
| Accounts receivable | -$5.2M | -$7.6M |
| Inventories | -$9.9M | -$11.4M |
| Prepaid expenses and other current assets | -$5.8M | -$2.8M |
| Other long-term assets | -$30.0K | -$29.0K |
| Accounts payable | $2.1M | $1.5M |
| Accrued expenses and other current liabilities | $7.4M | $6.8M |
| Other long-term liabilities | $1.5M | |
| Operating lease liability | -$1.2M | -$1.0M |
| Deferred revenue | $2.1M | $2.5M |
| Net cash used in operating activities | -$50.9M | -$48.3M |
| Purchases of short-term investments | -$282.0M | -$72.1M |
| Purchases of long-term investments | -$45.5M | |
| Proceeds from maturities and redemptions of short-term investments | $170.0M | $72.0M |
| Proceeds on disposal of property and equipment | $50.0K | |
| Purchases of property and equipment | -$5.3M | -$3.4M |
| Net cash used in investing activities | -$162.8M | -$3.5M |
| Proceeds from the issuance of common stock, net of underwriting discounts, commissions and issuance costs | $194.5M | |
| Proceeds from the issuance of common stock from private placement, net of issuance costs | $15.6M | |
| Proceeds from the issuance of convertible preferred stock, net of issuance costs | $59.7M | |
| Payments for deferred offering costs | -$4.1M | |
| Proceeds from stock option exercises | $4.8M | $89.0K |
| Proceeds from common stock warrants exercise | $13.0K | |
| Net cash provided by financing activities | $214.9M | $55.6M |
| Net increase in cash, cash equivalents and restricted cash | $1.1M | $3.9M |
| Deferred offering costs included in accrued expenses | $862.0K | |
| Reclassification of long-term investments to short-term investments | $171.1M | |
| Conversion of convertible preferred stock upon initial public offering | $321.4M | |
| Conversion of warrants net exercise upon initial public offering | $57.3M | |
| Reclassification of deferred offering costs to equity upon initial public offering | $5.1M | |
| Operating lease right-of-use asset obtained in exchange for operating lease obligations | $1.3M | $4.1M |
Former names
- Beta Bionics, IncMay 16, 2016 to Jan 6, 20252
Recent filings
- Oct 7, 2026SCHEDULE 13G
- Oct 5, 20264 PRIMARY DOCUMENT
- Oct 1, 2026144
- Sep 23, 20264
- Sep 22, 2026144
- Sep 18, 20264/A
- Sep 17, 2026424B5
- Sep 17, 20268-K
- Sep 17, 20264
- Sep 17, 20264
- Sep 16, 2026424B5
- Sep 16, 2026FWP
- Sep 16, 2026144
- Sep 16, 2026144
- Sep 15, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6